Genmab Geared Up To Launch Epkinly With AbbVie

As FDA Approves CD20xCD3 Bispecific For Lymphoma

22 May 2023

The Danish group, along with partner AbbVie, is all set for a commercial battle with Roche as Epkinly hits the US market for refractory diffuse large B-cell lymphoma a few weeks ahead of expected approval for the Swiss major’s same-in-class rival glofitamab.

Epkinly edges ahead of glofitamab • Source: Shutterstock

Genmab A/S is a newcomer when it comes to commercialization of drugs but the Danish biotech major is ready to hit the ground running with partner AbbVie Inc. and take on Roche Holding AG after getting the green light in the US for Epkinly, its bispecific antibody for lymphoma.

The US Food and Drug Administration has approved Epkinly (epcoritamab), a CD20xCD3 bispecific antibody, for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

09 May 2025

• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

09 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.